Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity

Journal of Dermatological Science

Volumn 83, Issue 3, 2016, Pages 167-173

  Fujimura, Taku ^a   Kakizaki, Aya ^a   Furudate, Sadanori ^a   Kambayashi, Yumi ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenetic factors; Chemokines; Immunosuppression; M2 polarization; Regulatory t cells; Tumor associated macrophages

Indexed keywords

CHEMOKINE; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL PLASTICITY; HOST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN CANCER; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; CELL COMMUNICATION; DRUG EFFECTS; IMMUNOLOGY; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHENOTYPE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SKIN; SKIN TUMOR; TH1 CELL;

ANGIOGENIC PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CHEMOKINES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MELANOMA; MOLECULAR TARGETED THERAPY; PHENOTYPE; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR MICROENVIRONMENT;

EID: 84991089534     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.05.015     Document Type: Review

References (50)

1. [1] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
2. [2] Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med., 7, 2015, 279ra41.
3. [3] Kakizaki, A., Fujimura, T., Furudate, S., Kambayashi, Y., Yamauchi, T., Yagita, H., et al. Immunomodulatory effect of peritumoral administration of interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology, 4, 2015, e1047584.
4. [4] Cyrus, N., Mai-Anh Bui, C., Yao, X., Kohn, L.L., Galan, A., Rhebergen, A.M., et al. Density and polarization states of tumor-associated macrophages in human cutaneous squamous cell carcinomas arising in solid organ transplant recipients. Dermatol. Surg., 2016 (in press).
5. [5] Seddon, A., Hock, B., Miller, A., Frei, L., Pearson, J., McKenzie, J., et al. Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells. J. Dermatol. Sci., 2016 (in press).
6. [6] Kambayashi, Y., Fujimura, T., Furudate, S., Asano, M., Kakizaki, A., Aiba, S., The possible interaction between receptor activator of nuclear factor kappa-B ligand (RANKL) expressed by extramammary Paget cells and its ligand on dermal macrophages. J. Invest. Dermatol. 135 (2015), 2547–2550.
7. [7] Fujimura, T., Kambayashi, Y., Furudate, S., Asano, M., Kakizaki, A., Aiba, S., Receptor activator of nuclear factor kappa-B ligand (RANKL) promotes the production of CCL17 from RANK+ M2 macrophages. J. Invest. Dermatol. 135 (2015), 2884–2887.
8. [8] Furudate, S., Fujimura, T., Kakizaki, A., Kambayashi, Y., Asano, M., Watabe, A., et al. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. Exp. Dermatol. 25 (2016), 107–112.
9. [9] Sugaya, M., Miyagaki, T., Ohmatsu, H., Suga, H., Kai, H., Kamata, M., et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J. Dermatol. Sci. 68 (2012), 45–51.
10. [10] Komohara, Y., Fujiwara, Y., Ohnishi, K., Takeya, M., Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv. Drug Deliv. Rev. 99:Pt B (2016), 180–185.
11. [11] Caronni, N., Savino, B., Bonecchi, R., Myeloid cells in cancer-related inflammation. Immunobiology 220 (2015), 249–253.
12. [12] Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454:7203 (2008), 436–444.
13. [13] Gocheva, V., Wang, H.W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L., et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 24 (2010), 241–255.
14. [14] Lin, E.Y., Gouon-Evans, V., Nguyen, A.V., Pollard, J.W., The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7 (2002), 147–162.
15. [15] Pettersen, J.S., Fuentes-Duculan, J., Suárez-Fariñas, M., Pierson, K.C., Pitts-Kiefer, A., Fan, L., et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J. Invest. Dermatol. 131 (2011), 1322–1330.
16. [16] Furudate, S., Fujimura, T., Kakizaki, A., Hidaka, T., Asano, M., Aiba, S., Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J. Dermatol. Sci., 2016 (in press).
17. [17] Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604.
18. [18] Wu, X., Schulte, B.C., Zhou, Y., Haribhai, D., Mackinnon, A.C., Plaza, J.A., et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J. Invest. Dermatol. 134 (2014), 2814–2822.
19. [19] Rodriguez, P.C., Quiceno, D.G., Ochoa, A.C., L-arginine availability reglates T-lymphocyte cell-cycle progression. Blood 109 (2007), 1568–1573.
20. [20] Fujimura, T., Mahnke, K., Enk, A.H., Myeloid derived suppressor cells and their role in tolerance induction in cancer. J. Dermatol. Sci. 59 (2010), 1–6.
21. [21] Zhang, Q., Qin, J., Zhong, L., Gong, L., Zhang, B., Zhang, Y., et al. CCL5-mediated th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res. 75 (2015), 4312–4321.
22. [22] Getts, D.R., Turley, D.M., Smith, C.E., Harp, C.T., McCarthy, D., Feeney, E.M., et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187 (2011), 2405–2417.
23. [23] Fujimura, T., Ring, S., Umansky, V., Mahnke, K., Enk, A.H., Regulatory T cells (Treg) stimulate B7-H1 expression in myeloid derived suppressor cells (MDSC) in ret melanomas. J. Invest. Dermatol. 132 (2012), 1239–1246.
24. [24] Linde, N., Lederle, W., Depner, S., van Rooijen, N., Gutschalk, C.M., Mueller, M.M., Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J. Pathol. 227 (2012), 17–28.
25. + T cell tolerance in cancer. Nat. Med. 13 (2007), 828–835.
26. [26] Ilkovitch, D., Lopez, D.M., Immune modulation by melanoma-derived factors. Exp. Dermatol. 17 (2008), 977–985.
27. [27] Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:7355 (2011), 222–225.
28. [28] Svensson, S., Abrahamsson, A., Rodriguez, G.V., Olsson, A.K., Jensen, L., Cao, Y., et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin. Cancer Res. 21 (2015), 3794–3805.
29. [29] Adeegbe, D.O., Nishikawa, H., Regulatory T cells in cancer; can they be controlled. Immunotherapy 7 (2015), 843–846.
30. [30] Lok, E., Chung, A.S., Swanson, K.D., Wong, E.T., Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Res. 24 (2014), 120–130.
31. [31] Fujimura, T., Kambayashi, Y., Furudate, S., Kakizaki, A., Hidaka, T., Asano, M., et al. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages. Exp. Dermatol., 2016 (in press).
32. [32] Zhang, Q., Qin, J., Zhong, L., Gong, L., Zhang, B., Zhang, Y., et al. CCL5-Mediated th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res. 75 (2015), 4312–4321.
33. [33] Kim, Y.H., Tavallaee, M., Sundram, U., Salva, K.A., Wood, G.S., Li, S., et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-Institution collaborative project. J. Clin. Oncol. 33 (2015), 3750–3758.
34. + lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Acta Derm. Venereol., 2015, 600–602.
35. [35] Günther, C., Zimmermann, N., Berndt, N., Grosser, M., Stein, A., Koch, A., et al. Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am. J. Pathol. 179 (2011), 1434–1442.
36. [36] Litvinov, I.V., Netchiporouk, E., Cordeiro, B., Doré, M.A., Moreau, L., Pehr, K., et al. The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL). Clin. Cancer Res. 21 (2015), 2820–2829.
37. [37] Werchau, S., Toberer, F., Enk, A., Dammann, R., Helmbold, P., Merkel cell carcinoma induces lymphatic microvessel formation. J. Am. Acad. Dermatol. 67 (2012), 215–225.
38. [38] Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N.R., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-Ligand. Cell 109 (2002), 625–637.
39. [39] Kale, S., Raja, R., Thorat, D., Soundararajan, G., Patil, T.V., Kundu, G.C., Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene 33 (2014), 2295–2306.
40. [40] Rogers, T.L., Holen, I., Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med., 9, 2011, 177.
41. [41] Melani, C., Sangaletti, S., Barazzetta, F.M., Werb, Z., Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67 (2007), 11438–11446.
42. [42] Mitchem, J.B., Brennan, D.J., Knolhoff, B.L., Belt, B.A., Zhu, Y., Sanford, D.E., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73 (2013), 1128–1141.
43. [43] Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190 (2013), 2464–2471.
44. [44] Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19 (2013), 57–64.
45. [45] Kodumudi, K.N., Woan, K., Gilvary, D.L., Sahakian, E., Wei, S., Djeu, J.Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16 (2010), 4583–4594.
46. [46] Fujimura, T., Yamasaki, K., Hidaka, T., Ito, Y., Aiba, S., A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-b synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth. J. Dermatol. Sci. 62 (2011), 107–115.
47. [47] Matsumoto-Okazaki, Y., Yamane, J., Kajiya, K., Real-time imaging of interaction between macrophages and lymphatic vessels in an in vitro model to study inflammatory resolution. J. Dermatol. Sci. 77 (2015), 76–79.
48. [48] Iwatsuki, K., Hamada, T., Japanese Skin Cancer Society – Lymphoma Study Group. current therapy of choice for cutaneous lymphomas: complementary to the Japanese Dermatological Association/Japanese Skin Cancer Society guidelines. J. Dermatol. 41 (2014), 43–49.
49. [49] Mills, C.D., Lenz, L.L., Harris, R.A., A Breakthrough: macrophage-directed cancer immunotherapy. Cancer Res. 76 (2016), 513–516.
50. [50] Gehrke, S., Otsuka, A., Huber, R., Meier, B., Kistowska, M., Fenini, G., et al. Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages. J. Dermatol. Sci. 74 (2014), 167–169.